Chordoma is an uncommon bone tumor that develops from residual cells of the embryonic notochord. It most frequently arises at the sacrum (lower spine) or the clivus (base of the skull). Although these tumors typically grow slowly, their location near vital anatomical structures often results in serious neurological and functional impairments. The chordoma meaning lies in its origin from embryonic notochordal remnants, distinguishing it from other bone tumors.
Characteristics and Classification
Histologically, chordomas are considered low-grade tumors; however, their invasive growth patterns and tendency for recurrence—even after surgery—pose significant clinical challenges.
Chordoma is a rare, slow-growing, malignant bone neoplasm originating from embryonic remnants of the primitive notochord along the axial skeleton. Most commonly arising at the clivus of the skull base or the sacrum, management requires high-precision neurosurgical resection, endoscopic skull base techniques, and targeted high-dose proton beam therapy.
Types of Chordoma
Chordomas are histopathologically classified into three distinct subtypes that determine biological behavior, invasiveness, and clinical prognosis:
1. Conventional (Classic) Chordoma
The predominant form, accounting for the vast majority of cases. Characterized histologically by physaliphorous, epithelioid cells producing abundant mucinous extracellular matrix and exhibiting slow, locally invasive growth.
2. Chondroid Chordoma
Exhibits pathological features overlapping with chondrosarcoma. Most frequently encountered in the spheno-occipital clival region and generally associated with a more favorable prognosis compared to classic forms.
3. Dedifferentiated Chordoma
The most aggressive and high-grade subtype. Characterized by rapid progression, loss of typical chordoma markers (such as brachyury), high metastatic potential, and extensive destruction of surrounding neurovascular structures.
A common clinical presentation is chordoma of the clivus, which leads to lower cranial nerve palsies, brainstem displacement, and base of skull compression. Known as clival chordoma, this anatomical variant demands a specialized skull base team due to its close proximity to the internal carotid arteries, basilar artery, and optic pathways. They are managed alongside other osseous and extradural lesions like adult spinal tumors, pediatric spinal tumors, and secondary metastatic spine cancer.
Common Symptoms of Chordoma
Clinical manifestations depend largely on the exact anatomical location along the axial skeleton (skull base, mobile spine, or sacrum). Recognizing early chordoma symptoms is essential for timely neurosurgical intervention:
- Head and Neck Pain: Tumors at the skull base cause persistent, deep-seated headaches and suboccipital pain due to dural stretch and bone erosion.
- Visual Problems & Cranial Nerve Deficits: Involvement of cranial nerves (CN III, IV, VI) leads to diplopia (double vision), ptosis, or partial vision loss.
- Swallowing & Speech Difficulties: Clival tumors extending into the lower skull base cause dysphagia, dysarthria, or tongue atrophy (CN IX, X, XII palsies).
- Limb Weakness & Radiculopathy: Mobile spine tumors compress exiting nerve roots or the spinal cord, causing radicular pain, paresthesias, or progressive motor weakness in arms or legs.
- Bowel and Bladder Dysfunction: Sacral chordomas frequently compress the cauda equina or sacral plexus, leading to urinary retention, fecal incontinence, and saddle anesthesia.
Diagnostic Evaluation
Diagnosing chordoma involves a thorough clinical neurological assessment combined with specialized multi-planar neuroimaging:
Neurological Examination
Detailed testing of cranial nerve pathways (especially ocular motility and lower cranial nerves), motor power, deep tendon reflexes, gait coordination, and sphincter tone.
Magnetic Resonance Imaging (MRI)
The gold standard for chordoma radiology. Characteristically demonstrates hyperintensity on T2-weighted MRI sequences, defining soft tissue extension, dural invasion, and compression of adjacent neural structures.
Computed Tomography (CT Scan)
Thin-slice bone algorithm CT provides detailed visualization of cortical bone destruction, lytic osseous erosion, calcification patterns, and assists in surgical route planning.
Treatment Strategies
Management depends on tumor subtype, anatomical resectability, and patient performance status:
1. Surgical Intervention
Surgery remains the primary treatment, aiming for maximal safe gross total resection while protecting neural pathways:
- Microsurgical Resection: Open transcranial or complex spinal approaches used for mobile spine or lateral skull base lesions.
- Endoscopic Endonasal Surgery: A minimally invasive technique utilizing transnasal corridors to directly access clival and midline skull base chordomas without brain retraction.
2. Advanced Radiation Therapy
Because chordomas are relatively radioresistant, specialized high-dose particle radiation is delivered postoperatively to control residual microscopic disease:
- Proton Beam Therapy: Delivers steep Bragg-peak dose distributions directly to the tumor bed while sparing critical adjacent structures (brainstem and optic nerves).
- Intensity-Modulated Radiation Therapy (IMRT): Customizes photon radiation beams to conform precisely to irregular tumor geometry.
3. Targeted Molecular Treatments
Specific molecular pathways identified in chordomas make selected recurrent or inoperable tumors susceptible to targeted systemic therapies. Tyrosine Kinase Inhibitors (such as imatinib or dasatinib) may slow disease progression by blocking platelet-derived growth factor receptors (PDGFR).
4. Chemotherapy
Although conventional cytotoxic chemotherapy is generally ineffective against classic chordomas, specialized combination chemotherapy regimens may be utilized in aggressive, high-grade dedifferentiated variants.
Prognosis
Despite their slow growth rate, chordomas represent significant clinical challenges due to their locally invasive nature, proximity to critical neurovascular structures, and tendency for local recurrence. Chordoma life expectancy and functional outcomes vary based on anatomical location, histopathological subtype, and the extent of primary surgical resection. Patients undergoing early, complete surgical resection followed by targeted proton beam therapy achieve significantly improved long-term local control.
Frequently Asked Questions
What is a chordoma?
A chordoma is a rare, slow-growing malignant bone tumor that develops from embryonic cell remnants of the primitive notochord along the skull base, spine, or sacrum.
What is a clival chordoma?
A clival chordoma is a specific skull base variant located in the clivus bone at the center of the head, behind the nasal passages and directly in front of the brainstem.
What are the primary symptoms of a skull base chordoma?
Common symptoms include persistent suboccipital or retro-orbital headaches, double vision (diplopia due to CN VI palsy), swallowing difficulties, and facial numbness.
How is an endoscopic endonasal surgery performed for chordoma?
Endoscopic endonasal surgery is a minimally invasive procedure where neurosurgeons access and remove the clival chordoma through the nasal cavity using specialized HD endoscopes and micro-instruments, avoiding facial or cranial incisions.
Why is proton beam therapy preferred for chordomas?
Because chordomas require high radiation doses to destroy, proton beam therapy allows radiation oncologists to deliver lethal doses to the tumor while sharply stopping radiation before it damages the adjacent brainstem or optic nerves.
Are chordomas cancerous?
Yes. Although slow-growing, chordomas are classified as malignant bone tumors because they destroy surrounding bone, invade local neural tissue, and can metastasize in advanced stages.